Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: A phase I/II randomized trial

Experimental Hematology and Oncology

Volumn 3, Issue 1, 2014, Pages

  Moran, Teresa ^a   Felip, Enriqueta ^b   Keedy, Vicki ^c   Borghaei, Hossein ^d   Shepherd, Frances A ^e   Insa, Amelia ^f   Brown, Holly ^g   Fitzgerald, Timothy ^g   Sathyanarayanan, Sriram ^g   Reilly, John F ^g   Mauro, David ^g   Hsu, Karl ^h   Yan, Li ^g   Johnson, David H ⁱ  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g MERCK RESEARCH LABORATORIES   (United States)

^h SANOFI   (France)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dalotuzumab; Epidermal growth factor receptor; Insulin growth factor receptor; Non small cell lung cancer; Phase I II trial

Indexed keywords

DALOTUZUMAB; ERLOTINIB;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARONYCHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SKIN TOXICITY; STOMATITIS; TREATMENT RESPONSE;

EID: 84983102615     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-3-26     Document Type: Article

References (16)

1. Takanami I, Imamuma T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S: Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 1996, 61:205-208.
2. Zia F, Jacobs S, Kull F Jr, Cuttitta F, Mulshine JL, Moody TW: Monoclonal antibody alpha IR-3 inhibits non-small-cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl 1996, 24:269-275.
3. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Nat Cancer Inst 1999, 91:151-156.
4. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, Daddi G, Cavaliere A, Tonato M, Crino L: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009, 20:842-849.
5. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small-cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007, 13:2795-2803.
6. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, Hanley W, Macarulla T, Rosello S, Baselga J: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MoAb) in patients (pts) with advanced solid tumors. In Presented at the 2008 ASCO Annual Meeting; May 31-June 3, 2010; Chicago, Ill. Abstract 3519. 2010.
7. Hidalgo M, Tirado Gomez M, Lewis N, Vulky JL, Taylor G, Hayburn JL, Hsu K, Kosh M, Picozzi VJ: A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. In Presented at the 2008 ASCO Annual Meeting; May 31-June 3, 2010; Chicago, Ill. Abstract 3520 2010.
8. NCI Common Terminology Criteria for Adverse Events Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm]
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 2000, 92:206-216.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, for the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Miller VA, Hirsch V, Cadrenel J, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
12. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005, 11:2063-2073.
13. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Piritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA: A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007, 6:2158-2167.
14. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S, Gualberto A: Phase II study of the anti-insulin like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522.
15. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A: Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). In Presented at the 2010 ASCO Annual Meeting; June 4-8, 2010; Chicago, Ill. Abstract 7500. 2010.
16. Ramalingam SS, Spiegel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K, Liu L, Janne PA, Brownstein CM, Reck M: Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011, 34:4574-4580.